Cargando…

Formulation of Poloxamers for Drug Delivery

Poloxamers, also known as Pluronics(®), are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which have an amphiphilic character and useful association and adsorption properties emanating from this. Poloxamers find use in many applications that require solubilization o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodratti, Andrew M., Alexandridis, Paschalis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872097/
https://www.ncbi.nlm.nih.gov/pubmed/29346330
http://dx.doi.org/10.3390/jfb9010011
_version_ 1783309763183902720
author Bodratti, Andrew M.
Alexandridis, Paschalis
author_facet Bodratti, Andrew M.
Alexandridis, Paschalis
author_sort Bodratti, Andrew M.
collection PubMed
description Poloxamers, also known as Pluronics(®), are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which have an amphiphilic character and useful association and adsorption properties emanating from this. Poloxamers find use in many applications that require solubilization or stabilization of compounds and also have notable physiological properties, including low toxicity. Accordingly, poloxamers serve well as excipients for pharmaceuticals. Current challenges facing nanomedicine revolve around the transport of typically water-insoluble drugs throughout the body, followed by targeted delivery. Judicious design of drug delivery systems leads to improved bioavailability, patient compliance and therapeutic outcomes. The rich phase behavior (micelles, hydrogels, lyotropic liquid crystals, etc.) of poloxamers makes them amenable to multiple types of processing and various product forms. In this review, we first present the general solution behavior of poloxamers, focusing on their self-assembly properties. This is followed by a discussion of how the self-assembly properties of poloxamers can be leveraged to encapsulate drugs using an array of processing techniques including direct solubilization, solvent displacement methods, emulsification and preparation of kinetically-frozen nanoparticles. Finally, we conclude with a summary and perspective.
format Online
Article
Text
id pubmed-5872097
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58720972018-03-30 Formulation of Poloxamers for Drug Delivery Bodratti, Andrew M. Alexandridis, Paschalis J Funct Biomater Review Poloxamers, also known as Pluronics(®), are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which have an amphiphilic character and useful association and adsorption properties emanating from this. Poloxamers find use in many applications that require solubilization or stabilization of compounds and also have notable physiological properties, including low toxicity. Accordingly, poloxamers serve well as excipients for pharmaceuticals. Current challenges facing nanomedicine revolve around the transport of typically water-insoluble drugs throughout the body, followed by targeted delivery. Judicious design of drug delivery systems leads to improved bioavailability, patient compliance and therapeutic outcomes. The rich phase behavior (micelles, hydrogels, lyotropic liquid crystals, etc.) of poloxamers makes them amenable to multiple types of processing and various product forms. In this review, we first present the general solution behavior of poloxamers, focusing on their self-assembly properties. This is followed by a discussion of how the self-assembly properties of poloxamers can be leveraged to encapsulate drugs using an array of processing techniques including direct solubilization, solvent displacement methods, emulsification and preparation of kinetically-frozen nanoparticles. Finally, we conclude with a summary and perspective. MDPI 2018-01-18 /pmc/articles/PMC5872097/ /pubmed/29346330 http://dx.doi.org/10.3390/jfb9010011 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bodratti, Andrew M.
Alexandridis, Paschalis
Formulation of Poloxamers for Drug Delivery
title Formulation of Poloxamers for Drug Delivery
title_full Formulation of Poloxamers for Drug Delivery
title_fullStr Formulation of Poloxamers for Drug Delivery
title_full_unstemmed Formulation of Poloxamers for Drug Delivery
title_short Formulation of Poloxamers for Drug Delivery
title_sort formulation of poloxamers for drug delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872097/
https://www.ncbi.nlm.nih.gov/pubmed/29346330
http://dx.doi.org/10.3390/jfb9010011
work_keys_str_mv AT bodrattiandrewm formulationofpoloxamersfordrugdelivery
AT alexandridispaschalis formulationofpoloxamersfordrugdelivery